riluzole has been researched along with Acute Post-Traumatic Stress Disorder in 2 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Veterans and active duty service members with combat-related PTSD (per the Clinician Administered PTSD Scale [CAPS]) who were not responsive to SSRI or SNRI pharmacotherapy were randomized to 8-week augmentation with a starting dose of 100 mg/d of riluzole (n = 36) or placebo (n = 38) and assessed weekly for PTSD symptoms, anxiety, depression, disability, and side effects." | 5.34 | Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms. ( Aliaga, P; Bartolanzo, D; Benedek, DM; Dempsey, CL; Possemato, K; Spangler, PT; Vythilingam, M; West, JC; Zarate, C, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Spangler, PT | 1 |
| West, JC | 1 |
| Dempsey, CL | 1 |
| Possemato, K | 1 |
| Bartolanzo, D | 1 |
| Aliaga, P | 1 |
| Zarate, C | 1 |
| Vythilingam, M | 1 |
| Benedek, DM | 1 |
| Rapp, A | 1 |
| Dodds, A | 1 |
| Walkup, JT | 1 |
| Rynn, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Riluzole for PTSD: Efficacy of a Glutamatergic Modulator as Augmentation Treatment for Posttraumatic Stress Disorder[NCT02155829] | Phase 1/Phase 2 | 75 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"CAPS is a 30-item structured interview that can be used to make current (past month) diagnoses of PTSD, make lifetime diagnoses of PTSD, and assess PTSD symptoms over the past week.~A summed score of 17 items:~Minimum Score: 0 (no symptoms)~Maximum Score: 136 (very severe symptoms)~Subscales:~Subscale B (re-experiencing): items 1-5, a score of 0-40. Subscale C (avoidance): items 6-12, a score of 0-56. Subscale D (hyperarousal): items 13-17, a score of 0-40.~CAPS scores were measured at baseline, mid-treatment, and post-treatment. For outcome analyses, differences between pre-treatment and post-treatment scores were used." (NCT02155829)
Timeframe: Week 1 and 8
| Intervention | score on a scale (Mean) |
|---|---|
| Riluzole | -21.1 |
| Placebo | -16.7 |
"Subscale D (items 13-17 on the CAPS-IV) measures Hyperarousal symptoms of PTSD~Scoring: A sum of items 13-17. Minimum: 0 (no symptoms) Maximum: 40 (very severe symptoms)~CAPS-D scores were measured at baseline, mid-treatment, and post-treatment. For outcome analyses, differences between pre-treatment and post-treatment scores were used." (NCT02155829)
Timeframe: Week 1 and 8
| Intervention | score on a scale (Mean) |
|---|---|
| Riluzole | -6.8 |
| Placebo | -3.7 |
"A 14-item clinician-administered assessment measuring anxiety symptoms.~Scoring: A sum of all 14 items. Minimum: 0 (no symptoms) Maximum: 56 (very severe symptoms)~HAM-A scores were measured at baseline, mid-treatment, and post-treatment. For outcome analyses, differences between pre-treatment and post-treatment scores were used." (NCT02155829)
Timeframe: Week 1 and 8
| Intervention | score on a scale (Mean) |
|---|---|
| Riluzole | -7.8 |
| Placebo | -6.7 |
"A ten-item diagnostic questionnaire to measure the severity of depressive episodes.~Scoring: A sum of all 10 items. Minimum: 0 (no symptoms) Maximum: 60 (very severe symptoms)~MADRS scores were measured at every study visit. For outcome analyses, differences between pre-treatment and post-treatment scores were used." (NCT02155829)
Timeframe: Week 1 and 8
| Intervention | score on a scale (Mean) |
|---|---|
| Riluzole | -7.9 |
| Placebo | -8.2 |
"A 17-item self-report measure used to assess PTSD symptoms related to a specific traumatic event.~Scoring: A sum of all 17 items. Minimum: 17 (no symptoms) Maximum: 85 (very severe symptoms)~PCL-S scores were measured at every study visit. For outcome analyses, differences between pre-treatment and post-treatment scores were used." (NCT02155829)
Timeframe: Week 1 and 8
| Intervention | score on a scale (Mean) |
|---|---|
| Riluzole | -15.4 |
| Placebo | -14.5 |
"The subscale D (items 13-17 on the PCL) measures hyperarousal symptoms of PTSD. Scoring: A sum of items 13 to 17. Minimum: 5 (no symptoms) Maximum: 25 (very severe symptoms)~PCL-D scores were measured at baseline, mid-treatment, and post-treatment. For outcome analyses, differences between pre-treatment and post-treatment scores were used." (NCT02155829)
Timeframe: Week 1 and week 8
| Intervention | score on a scale (Mean) |
|---|---|
| Riluzole | -5.9 |
| Placebo | -3.4 |
"A 3-item self-report measure to assess functional impairment in work/school, social, and family life.~Scoring: A sum of all 3 items. Minimum: 0 (no symptoms) Maximum: 30 (very severe symptoms)~SDS scores were measured at baseline, mid-treatment, and post-treatment. For outcome analyses, differences between pre-treatment and post-treatment scores were used." (NCT02155829)
Timeframe: Week 1 and 8
| Intervention | score on a scale (Mean) |
|---|---|
| Riluzole | -6.3 |
| Placebo | -5.7 |
1 review available for riluzole and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Treatment of pediatric anxiety disorders.
Topics: Adolescent; Anticonvulsants; Anxiety Disorders; Anxiety, Separation; Child; Cognitive Behavioral The | 2013 |
1 trial available for riluzole and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms.
Topics: Adult; Anxiety; Depression; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Excitato | 2020 |